Last reviewed · How we verify
Mitomycin, doxifluridine and cisplatin
This combination of three chemotherapy agents works by damaging DNA and inhibiting nucleotide synthesis to kill rapidly dividing cancer cells.
This combination of three chemotherapy agents works by damaging DNA and inhibiting nucleotide synthesis to kill rapidly dividing cancer cells. Used for Gastric cancer (Phase 3 trial indication).
At a glance
| Generic name | Mitomycin, doxifluridine and cisplatin |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination (alkylating agent, antimetabolite, platinum agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mitomycin is an alkylating agent that cross-links DNA strands; doxifluridine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA; cisplatin is a platinum compound that forms DNA adducts. Together, they provide synergistic cytotoxic effects against cancer cells through multiple mechanisms of DNA damage and replication inhibition.
Approved indications
- Gastric cancer (Phase 3 trial indication)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Diarrhea
- Anemia
- Mucositis
- Nephrotoxicity
Key clinical trials
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin, doxifluridine and cisplatin CI brief — competitive landscape report
- Mitomycin, doxifluridine and cisplatin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI